Preparing the published article.
MMI: Symani Robotic Microsurgery and NanoWrist Instruments
Review Medical Microinstruments and Symani, surgeon-controlled motion scaling, NanoWrist instruments and regional indication differences, with hospital program and procurement considerations.
Company identity and history
MMI stands for Medical Microinstruments, Inc. Its official history records founding in Pisa, Italy, in 2015 and corporate redomiciliation to the United States in 2022. The same timeline records European launch and first human use in 2020, followed by a commercial installation at University Hospital Salzburg in 2021. These are dated company statements, not an independently audited current installation count.
Symani and surgeon control
The Symani Surgical System combines miniaturized instruments, tremor reduction and motion scaling for open microsurgery. MMI describes motion scaling as translating the surgeon's larger hand movements into smaller instrument movements. The robot assists a trained physician; the description does not support autonomous selection of a surgical action or a claim that the device replaces clinical judgement.
NanoWrist and visualization
The manufacturer describes Micro and SuperMicro instrument families, together with scissors and forceps for tissue manipulation. Instrument choice is part of the configuration, not simply a software setting. MMI states that the platform can work with optical microscopes, hybrid microscopes and three-dimensional exoscopes. Confirm the actual instrument list and visualization setup for the proposed installation rather than assuming every accessory is included.
Regional indication boundaries
MMI's current indication page distinguishes the United States from Europe and selected Asia-Pacific countries. The US description concerns trained physicians treating adults and specifies particular open microsurgical applications. The European and selected APAC description includes adult and pediatric use and nerves, while excluding the heart, central circulatory system and central nervous system. These regional statements must not be merged into a single worldwide indication.
Dated authorization and evidence
MMI announced US De Novo authorization on 8 April 2024. That announcement is a historical regulatory milestone, not proof that every later instrument or application is covered by the original authorization. The current product pages reference studies and clinical experience. A hospital evaluation should inspect the underlying study population, procedure and limitations instead of treating marketing percentages as a universal expected outcome.
Developing a hospital program
A purchasing team should consider the surgeon and theatre team's training, visualization equipment, instrument availability and workflow together. Establish who will provide installation records, initial training, technical support and maintenance. Define a documented evaluation and institutional approval process before clinical introduction. The directory provides no procedural instructions and does not determine whether an individual patient is suitable for microsurgery.
Commercial and support requirements
Ask for the legal seller, local service arrangements, exact system and instrument versions, current instructions for use and applicable destination documentation. Separate capital equipment, recurring instruments, training and software services in the quotation. Confirm replacement lead times and support for equipment already in the operating room. Neither authorization nor a supplier's case history establishes reimbursement, cost savings or delivery dates for a new customer.
Sources and review boundary
Reviewed 11 September 2026: MMI history, Symani design and instruments, regional indications, and dated US authorization announcement. Indication summaries are attributed to the manufacturer and require confirmation against current local documentation; no general clinical-outcome claim is made.